Do Lactobacillus rhamnosus or casei reduce respiratory tract infection risk?
This conversation clarifies the taxonomy of Lactobacillus casei rhamnosus and reviews evidence for L. rhamnosus GG and L. casei Shirota in reducing risk, duration, and severity of respiratory tract infections. The effect is modest, strain-specific, and more pronounced in children, elderly, and athletes.
Does Lactobacillus casei rhamnosus actually help reduce the risk of respiratory tract infections?
To clarify, "Lactobacillus casei rhamnosus" isn't a standard taxonomic designation. You're likely referring to either Lactobacillus rhamnosus (now Lacticaseibacillus rhamnosus) or Lactobacillus casei (now Lacticaseibacillus casei). The most well-studied strain is Lactobacillus rhamnosus GG (LGG).
What the evidence suggests
Lactobacillus rhamnosus
- Several clinical trials and meta-analyses have found that L. rhamnosus (particularly the GG strain) may modestly reduce the risk of acquiring respiratory tract infections (RTIs), especially in children and older adults.
- It has also been associated with a shorter duration of respiratory infections and reduced severity of symptoms, including fewer days of missed work or school.
- However, the effect size is generally modest, and not all studies have shown statistically significant benefits.
Lactobacillus casei
- L. casei (particularly the Shirota strain found in fermented dairy drinks) has also been studied for RTI prevention, with some evidence suggesting a reduction in the incidence of upper respiratory tract infections.
- Results are mixed, with some studies showing benefit primarily in specific populations (e.g., elderly individuals, athletes under heavy training).
Important caveats
- Strain-specific effects — Probiotic benefits are highly strain-specific. Results for L. rhamnosus GG cannot be assumed to apply to other strains of L. rhamnosus or L. casei.
- Modest effect — The reduction in risk is generally modest, not a guarantee of prevention.
- Population matters — Benefits appear stronger in populations with higher baseline risk (e.g., children in daycare, elderly, athletes).
- Mechanism — Probiotics may support immune function by modulating the gut microbiota, enhancing mucosal immunity, and reducing inflammation, but the exact mechanisms are still being studied.
In summary — yes, there is evidence that Lactobacillus rhamnosus and Lactobacillus casei can help reduce the risk and duration of respiratory tract infections, but the effect is modest, strain-dependent, and more pronounced in certain populations. It's not a replacement for standard preventive measures like vaccination and good hygiene.
Would you like me to search for specific products containing these probiotics?